title: [Hemodilution therapy in patients with acute anterior ischemic optic neuropathy].
abstract: A prospective study was performed in 22 patients with an anterior ischaemic optic neuropathy (AION). All patients underwent iso- (Hct > or = 42%) or hypervolemic (Hct < 42%) haemodilution for 10 days with daily infusion of 250 ml hydroxyethyl starch (MW 200,000/0.5, 10% HAES-sterile) in combination with pentoxifylline (p.o.: 1200 mg/day; i.v.: 300 mg/day; Trental). Only patients with recent AION (less than 2 weeks' duration of symptoms) were considered for the prospective trial. Clinical, haemodynamic (arterio-venous passage time) and rheological (haematocrit, plasma viscosity, erythrocyte aggregation) data of all patients were recorded before therapy and after 10 days. An improvement of central vision by 2 or more lines was seen in 7 patients after 10 days. Initially the arterio-venous passage time was significantly prolonged in patients (2.42 +/- 0.7 s) with AION compared with healthy volunteers (1.45 +/- 0.4 s). After the 10-day trial arterio-venous passage time was significantly shorter than baseline values. In addition, the initially elevated plasma viscosity (1.33 +/- 0.1 mPa) was significantly lowered by haemodilution therapy.
authors.affiliation: Augenklinik, Medizinische Fakultät der RWTH, Aachen.
authors.forename: S
authors.initials: S
authors.lastname: Wolf
authors.forename: U
authors.initials: U
authors.lastname: Schulte-Strake
authors.forename: B
authors.initials: B
authors.lastname: Bertram
authors.forename: K
authors.initials: K
authors.lastname: Schulte
authors.forename: O
authors.initials: O
authors.lastname: Arend
authors.forename: M
authors.initials: M
authors.lastname: Reim
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003925:Diabetic Angiopathies / Q000150:complications / Q000175:diagnosis; D005260:Female; D006438:Hemodilution / Q000379:methods*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage; D007262:Infusions, Intravenous; D007511:Ischemia / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009900:Optic Nerve / Q000098:blood supply*; D009902:Optic Neuritis / Q000209:etiology / Q000628:therapy*; D010211:Papilledema / Q000209:etiology / Q000628:therapy*
chemical_list: D006895:Hydroxyethyl Starch Derivatives
vernacular_title: Hämodilutionstherapie bei Patienten mit akuter vorderer ischämischer Optikusneuropathie.